These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22732368)
21. [An overview of clinical trials in endocrine therapy for cancer]. Hinotsu S; Ohasi Y; Akaza H Gan To Kagaku Ryoho; 1996 May; 23(6):689-94. PubMed ID: 8645019 [TBL] [Abstract][Full Text] [Related]
22. A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Maximov PY; Abderrahman B; Curpan RF; Hawsawi YM; Fan P; Jordan VC Endocr Relat Cancer; 2018 Feb; 25(2):R83-R113. PubMed ID: 29162647 [TBL] [Abstract][Full Text] [Related]
23. Breaking through a roadblock in prostate cancer research: an update on human model systems. Toivanen R; Taylor RA; Pook DW; Ellem SJ; Risbridger GP J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):122-31. PubMed ID: 22342674 [TBL] [Abstract][Full Text] [Related]
24. Hormone-refractory prostate cancer: what have we learned? Wirth MP BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362 [No Abstract] [Full Text] [Related]
27. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines. Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040 [TBL] [Abstract][Full Text] [Related]
28. Prostate cancer drugs. Making sense of the options. Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308 [No Abstract] [Full Text] [Related]
29. [Current role of chemotherapy in the treatment of hormone-resistant prostatic cancer]. Soulie M; Beuzeboc P; Irani J; Davin JL Prog Urol; 2006 Jun; 16(3):394-5. PubMed ID: 16821362 [No Abstract] [Full Text] [Related]
30. Adjuvant hormonal therapy for premenopausal women with breast cancer. Brown RJ; Davidson NE Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345 [TBL] [Abstract][Full Text] [Related]
31. [Hormonal aspects and hormone therapy of cancer]. Klijn JG Ned Tijdschr Geneeskd; 1991 Dec; 135(50):2369-75. PubMed ID: 1749441 [No Abstract] [Full Text] [Related]
32. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Dunn BK; Ford LG Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094 [TBL] [Abstract][Full Text] [Related]
33. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. Pitts WR BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186 [No Abstract] [Full Text] [Related]
35. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. Schally AV BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347 [No Abstract] [Full Text] [Related]
36. Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy. Figg WD; Feuer JA; Bauer KS Cancer Pract; 1997; 5(4):258-63. PubMed ID: 9250085 [No Abstract] [Full Text] [Related]
37. Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction. Gomella LG BJU Int; 2007 Jan; 99 Suppl 1():1. PubMed ID: 17229158 [No Abstract] [Full Text] [Related]
38. Ketoconazole as a secondary hormonal intervention in advanced prostate cancer. Liebertz C; Fox P Clin J Oncol Nurs; 2006 Jun; 10(3):361-6. PubMed ID: 16789581 [No Abstract] [Full Text] [Related]
39. Multiple intracrine hormonal targets in the prostate: opportunities and challenges. Labrie F BJU Int; 2007 Jul; 100 Suppl 2():48-51. PubMed ID: 17594360 [No Abstract] [Full Text] [Related]
40. A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer. Higgins GS; Stewart GD; McNeill SA; McLaren DB Int J Clin Pract; 2007 Dec; 61(12):1964-5. PubMed ID: 17997800 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]